Correction to: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy (Annals of Hematology, (2025), 104, 10, (5223-5236), 10.1007/s00277-025-06602-9)

1

Issued Date

2026-03-01

Resource Type

Erratum

ISSN

09395555

eISSN

14320584

DOI

10.1007/s00277-026-06880-x

Scopus ID

2-s2.0-105029868499

Journal Title

Annals of Hematology

Volume

105

Issue

3

Rights Holder(s)

SCOPUS

Bibliographic Citation

Annals of Hematology Vol.105 No.3 (2026)

Suggested Citation

Jiang B., Li J., Liu L., Du X., Jiang H., Hu J., Zeng X., Sakatani T., Kosako M., Deng Y., Ivanov V., Bondarenko S., Lee L.W.L., Khuhapinant A., Martynova E., Hasabou N., An J.J.H., Wang J. Correction to: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy (Annals of Hematology, (2025), 104, 10, (5223-5236), 10.1007/s00277-025-06602-9). Annals of Hematology Vol.105 No.3 (2026). doi:10.1007/s00277-026-06880-x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115166

Title

Correction to: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy (Annals of Hematology, (2025), 104, 10, (5223-5236), 10.1007/s00277-025-06602-9)

Author(s)

Jiang B.
 Li J.
 Liu L.
 Du X.
 Jiang H.
 Hu J.
 Zeng X.
 Sakatani T.
 Kosako M.
 Deng Y.
 Ivanov V.
 Bondarenko S.
 Lee L.W.L.
 Khuhapinant A.
 Martynova E.
 Hasabou N.
 An J.J.H.
 Wang J.

Author's Affiliation

Fujian Medical University
 Peking Union Medical College Hospital
 Peking University People's Hospital
 Siriraj Hospital
 Guangdong Provincial People’s Hospital of Southern Medical University
 Astellas Pharma Inc., Japan
 Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
 Almazov National Medical Research Centre
 Tongren Hospital Shanghai Jiao Tong University School Of Medicine
 Peking University International Hospital
 Astellas Pharma US, Inc.
 Ltd.
 Pavlov University
 Krasnoyarsk Regional Clinical Hospital
 Queen Elizabeth Hospital

Corresponding Author(s)

Jiang B.

Other Contributor(s)

Mahidol University

Abstract

In the published paper, the median event-free survival of the gilteritinib arm was incorrectly presented in Fig. 4. The median value ‘21’ should be presented as ‘2.1’. The original article has been corrected.

Keyword(s)

Medicine

Availability

URI

https://repository.li.mahidol.ac.th/handle/123456789/115166

Collections

Scopus 2026